CXCL8 and cancer: The miR-146b-5p/IRAK (Interleukin-1 receptor-associated kinase 1) interaction also suppresses NF-κB, inhibiting the production of IL-6 (interleukin-6) and IL-8 (interleukin-8), which contribute to osimertinib resistance in this type of cancer [97].